Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.

@article{Sun2017RomidepsinIG,
  title={Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.},
  author={Wei-jian Sun and He Huang and Bin He and D Hu and Pi-Hong Li and Yao-Jun Yu and Xiao-hu Zhou and Zhen Zhen Lv and Lei Zhou and T Hu and Zhi-Chao Yao and Ming-dong Lu and Xian Shen and Zhi-qiang Zheng},
  journal={Biochemical pharmacology},
  year={2017},
  volume={127},
  pages={90-100}
}
The aim of the study is to demonstrate the effect of Romidepsin in hepatocellular carcinoma (HCC) by inducing G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis through JNK/c-Jun/caspase3 pathway in vitro and in vivo. Human HCC cell lines were cultured with Romidepsin and DMSO (negative control) and 5-fluorouracil (positive control). Then the cells' viability and apoptosis were determined by cell proliferation assay and flow cytometry. Protein concentrations and expression… CONTINUE READING